Patents Assigned to HITOPS GmbH
  • Patent number: 9162075
    Abstract: The invention relates to a method for medical treatment of a mammal, preferably a human, by applying pulsed radiofrequency (PRF) stimulation intravascularly. More particularly, said method has as effect that it boosts the immune system and/or that it relieves pain. In a preferred embodiment, the disease or condition to be treated is caused or accompanied by immunodeficiency, more preferably the disease or condition is selected from the group of cancer, infectious diseases, immunosuppression or otherwise caused immunodeficiencies. Also auto-immune diseases and conditions associated with allostatic load are preferred for treatment with the method of the invention. In an also preferred embodiment, the PRF stimulation is applied together with vaccination.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: October 20, 2015
    Assignee: HITOPS GMBH
    Inventors: Menno Emanuel Sluijter, Alexandre Jose Leonardo Teixeira
  • Publication number: 20140296948
    Abstract: The invention relates to a method for medical treatment of a mammal, preferably a human, suffering from cancer by applying pulsed radiofrequency (PRF) stimulation before chemotherapy or hormonal therapy. The PRF treatment may be given intravascularly or transcutaneously. In another embodiment, PRF treatment is performed through transcutaneous application of the signal.
    Type: Application
    Filed: March 27, 2013
    Publication date: October 2, 2014
    Applicant: HITOPS GmbH
    Inventor: Menno Emanuel Sluijter
  • Publication number: 20130079835
    Abstract: The invention relates to a method for medical treatment of a mammal, preferably a human, by applying pulsed radiofrequency (PRF) stimulation intravascularly. More particularly, said method has as effect that it boosts the immune system and/or that it relieves pain. In a preferred embodiment, the disease or condition to be treated is caused or accompanied by immunodeficiency, more preferably the disease or condition is selected from the group of cancer, infectious diseases, immunosuppression or otherwise caused immunodeficiencies. Also auto- immune diseases and conditions associated with allostatic load are preferred for treatment with the method of the invention. In an also preferred embodiment, the PRF stimulation is applied together with vaccination.
    Type: Application
    Filed: December 23, 2010
    Publication date: March 28, 2013
    Applicant: HITOPS GmbH
    Inventors: Menno Emanuel Sluijter, Alexandre Jose Leonardo Teixeira